Publication | Closed Access

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

VaccinationVaccine SafetyVaccinologyGlobal HealthVaccine SurveillanceVaccine TestingVaccine EfficacyLatin AmericaPublic HealthMedicineHealthy ChildrenArbovirusEpidemiologyVector Borne DiseaseTetravalent Dengue Vaccine